Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05373-8 ↗Kurz gefasst
Leitlinie in der Zeitschrift World Journal of Urology, 2024. Verfasst von Giuseppe Chiarelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting, Guideline Adherence, Practice Guidelines as Topic. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To assess active surveillance (AS) adherence for prostate cancer (PCa) in a "real-world" clinical practice. MATERIALS AND METHODS: We utilized our institutional database which was built by interrogating electronic medical records for all men who got diagnosed with PCa from 1995 to 2022. Our cohort included all patients aged < 76 years, with PCa Gleason Grade (GG) 1 or 2, ≤ cT2c, PSA ≤ 20 ng/ml at diagnosis, enrolled on AS, and with at least one biopsy after diagnosis. Patients were separated into two groups based on the monitoring intensity. Patients with at least 1 PSA/year and at least 1 biopsy every 4 years were categorized as adherent to guidelines. Univariable and Multivariable logistic regression analyses were used to examine the impact of covariates on non-adherence to guidelines. Competing risks cumulative incidence was used to depict prostate cancer-specific mortality (PCSM). RESULTS: A total of 546 men met the inclusion criteria. Overall, 63 (11%) patients were adherent to guidelines (Group 1), while 483 (89%) were not (Group 2). Median PSAs/year and median biopsies/year were 2.3 (2.0-2.7) and 0.4 (0.3-0.6) for Group 1, and 1.2 (0.7-1.8) and 0.2 (0.1-0.2) for Group 2, respectively (both p < 0.0001). At multivariable analysis, Black men had a 2.20-fold higher risk of being in Group 2 than White men (p < 0.05). Patients with cT2 (OR:0.24, CI:0.11-0.52) and those with CCI ≥2 (OR:0.40, CCI:0.19-0.82) were less likely to be in Group 2, when compared to cT1 stage and CCI = 0, respectively (both p < 0.05). At 10 years, the cumulative incidence estimate of PCSM for the entire cohort was 2.1%. CONCLUSION: We found substantial deviations from AS monitoring guidelines, particularly in biopsy frequency, which did not seem to compromise PCSM in patients with stable PSA. Notably, our findings suggest that strict adherence to guidelines, especially in patients with cT2 at diagnosis, remains crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
- Department of Urology, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy.
- Public Health Sciences, Henry Ford Health System, Detroit, MI, USA.
- Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
- Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Zitieren
APA
Chiarelli, G., Stephens, A., Finati, M., Cirulli, G. O., Tinsley, S., Wang, Y., Kolanukuduru, K., Sood, A., Carrieri, G., Briganti, A., Montorsi, F., Lughezzani, G., Buffi, N., Rogers, C., & Abdollah, F. (2024). Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice. World Journal of Urology. https://doi.org/10.1007/s00345-024-05373-8
Vancouver
Chiarelli G, Stephens A, Finati M, Cirulli GO, Tinsley S, Wang Y, et al. Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice. World Journal of Urology. 2024. doi:10.1007/s00345-024-05373-8
BibTeX
@article{Chiarelli2024,
author = {Chiarelli, Giuseppe and Stephens, Alex and Finati, Marco and Cirulli, Giuseppe Ottone and Tinsley, Shane and Wang, Yuzhi and Kolanukuduru, Kaushik and Sood, Akshay and Carrieri, Giuseppe and Briganti, Alberto and Montorsi, Francesco and Lughezzani, Giovanni and Buffi, Nicolò and Rogers, Craig and Abdollah, Firas},
title = {Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05373-8}
}
EUVIMED